Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §2

Thymalin — pharmacology

Molecular targets, mechanism of action, pharmacokinetics and interactions as characterised in humans.

Document identifier
CEI-MN-041/2
Series
Compound monograph
Version
4.1
Published
15 Oct 2025
Last reviewed
15 Jul 2026
Next review
15 Jul 2028
Identifier
10.71829/cei.mono.41
Certainty
Very low
Cycle
2025 Q4

§2Pharmacology

§2.1Molecular targets

Table 2. Molecular targets recorded for Thymalin, with the character of the interaction and the potency where the Institute holds it.

TargetInteractionNote
UndefinedExtract of undefined compositionNo molecular target can be assigned to a substance whose active components are not identified

§2.2Mechanism of action

Thymalin is a fractionated calf-thymus extract registered in the Russian Federation as an immunomodulator. Because its composition is not defined, no mechanism can be stated at molecular level, and batch-to-batch consistency is governed by the extraction process rather than by a chemical specification.[1,2]

§2.3Pharmacokinetics

Terminal half-life
not applicable to an undefined mixture
Time to maximum concentration
not applicable
Volume of distribution
not applicable
Plasma protein binding
not applicable
Clearance
not applicable
Bioavailability
not applicable

Not characterisable for a mixture of undefined composition.

Reconstructed plasma concentration–time profilePlasma concentration plotted against time after dosing, reconstructed from published pharmacokinetic parameters.0.00.20.40.60.8020406080Time after first dose (hours)Relative concentrationt max ≈ 11 ht½ ≈ 24 h
Modelled profileSimulated observationsDose administration
Figure 2. Illustrative. Plasma concentration–time profile reconstructed by the Institute from the published half-life and time-to-maximum-concentration parameters using a one-compartment model with first-order absorption. The curve is not digitised from a published figure and its vertical scale is relative. It is published to convey the shape of the profile and the approach to steady state, not to supply a concentration at any time point.

§2.4Interactions

  • Immunosuppressants — pharmacodynamic antagonism

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. United States Pharmacopeial Convention. General Chapter ⟨85⟩ Bacterial Endotoxins Test. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
  2. United States Pharmacopeial Convention. General Chapter ⟨71⟩ Sterility Tests. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Compound Evidence Institute · CEI-MN-041/2 · https://compoundevidence.com/monographs/thymalin/pharmacology/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.